Phaseline

Companies › Rovi Pharmaceuticals Laboratories

Rovi Pharmaceuticals Laboratories: clinical trials, targets and expected readouts

1 active drug program in 43 registered trials: 26 Phase 2, 11 Phase 3, 4 Phase 4, 2 Phase 1; Genitourinary, Metabolic and endocrine, Oncology, Other; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Letrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 1Hormone Receptor Positive Early Breast Cancer; Polycystic Ovary Syndrome; Abortion in First Trimester; Miscarriage in First Trimester …May 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT00999804LetrozolePhase 2Breast CancerOncologyNov 2014
NCT05206448LetrozolePhase 4Polycystic Ovary SyndromeMetabolic and endocrineApr 2024
NCT04272801LetrozolePhase 2Breast Cancer FemaleOncologyJun 2024
NCT06244745LetrozolePhase 3Luteinised Follicular CystGenitourinaryMay 2025
NCT05341817LetrozolePhase 4Abortion in First TrimesterOtherAug 2025
NCT07160855LetrozolePhase 4Miscarriage in First TrimesterOtherNov 2025
NCT05190094LetrozolePhase 2Hormonal Receptors Positive, HER2 Negative, Advanced Breast CancerOncologyDec 2025
NCT07616973LetrozolePhase 3Infertility DrugsMetabolic and endocrineMay 2026
NCT04486911LetrozolePhase 2Breast CancerOncologyDec 2026
NCT04393285LetrozolePhase 2Endometrial CancerOncologyDec 2026
NCT07842796LetrozolePhase 2Ectopic PregnancyOtherDec 2026
NCT06354439LetrozolePhase 4Ectopic PregnancyOtherDec 2026
NCT03673124LetrozolePhase 2Low Grade Serous CarcinomaOncologyDec 2026
NCT01272037LetrozolePhase 3Breast Ductal Carcinoma In SituOncologyJan 2027
NCT04095364LetrozolePhase 3Low Grade Fallopian Tube Serous AdenocarcinomaOncologyFeb 2027
NCT05247268LetrozolePhase 2Endometrial Neoplasm Malignant Stage IOncologyMar 2027
NCT06394804LetrozolePhase 2Low-Grade Serous Ovarian CancerOncologyApr 2027
NCT05472792LetrozolePhase 2Breast CancerOncologyApr 2027
NCT05900206LetrozolePhase 2Breast CancerOncologyApr 2027
NCT04111978LetrozolePhase 3Ovarian Neoplasm EpithelialOncologyJul 2027
NCT06390904LetrozolePhase 2Atypical Endometrial HyperplasiaMetabolic and endocrineJul 2027
NCT06366347LetrozolePhase 2Endometrial CancerOncologySep 2027
NCT07014410LetrozolePhase 2Breast CancerOncologyDec 2027
NCT05872204LetrozolePhase 2Low Grade Serous Ovarian CarcinomaOncologyJan 2028
NCT05316935LetrozolePhase 2Endometrial NeoplasmsOncologyMar 2028
NCT06379113LetrozolePhase 2Endometrial NeoplasmsOncologyMar 2028
NCT04568616LetrozolePhase 2Breast CancerOncologyApr 2028
NCT01068249LetrozolePhase 2Endometrial CancerOncologyApr 2028
NCT07401381LetrozolePhase 1Hormone Receptor Positive Early Breast CancerOncologyMay 2028
NCT05649956LetrozolePhase 2Uterine LeiomyosarcomaOncologyJul 2028
NCT06044623LetrozolePhase 3Metastatic Breast CancerOncologyOct 2028
NCT03900637LetrozolePhase 2Breast CancerOncologyDec 2028
NCT02221999LetrozolePhase 2Tubular Breast CancerOncologyJan 2029
NCT06276868LetrozolePhase 2Breast CancerOncologyJun 2029
NCT06507618LetrozolePhase 3Breast Cancer FemaleOncologyJun 2029
NCT05601700LetrozolePhase 3Carcinoma, Ovarian EpithelialOncologySep 2029
NCT07483307LetrozolePhase 2Breast CancerOncologyMar 2030
NCT04134598LetrozolePhase 3Breast CancerOncologyMar 2030
NCT00310180LetrozolePhase 3Breast AdenocarcinomaOncologySep 2030
NCT05297617LetrozolePhase 2Breast CancerOncologyNov 2030
NCT04852887LetrozolePhase 3Stage I Breast CancerOncologyApr 2031
NCT06139107LetrozolePhase 1Breast CancerOncologySep 2032
NCT04293393LetrozolePhase 2Early Breast CancerOncologyFeb 2033

Targets

CYP19A1 (1)

Companies with the same targets

ReproNovo Aps

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.